EdwardAnthonyFaberJr.DOM.S.
Hematology • Cincinnati, OHHematologic Oncology
Director, Adult BMT & Cellular Therapy Associate Professor, Hematology/Oncology
Dr. Faber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3125 Eden Avenue
ML0562, Room 3116
Cincinnati, OH 45267Phone+1 513-558-2621Fax+1 513-558-2124
Summary
- Dr. Edward Faber is a hematologist in Cincinnati, OH and is affiliated with the University of Cincinnati Medical Center. He currently serves as the Director of Adult BMT & Cellular Therapy, and an Associate Professor of Hematology/Oncology. He received his medical degree from Lake Erie College of Osteopathic Medicine and has been in practice 14 years.
Education & Training
McLaren Health Care/Greater Lansing/MSUFellowship, Hematology and Medical Oncology, 2006 - 2009
UPMC Medical Education/MercyResidency, Internal Medicine, 2003 - 2006- Lake Erie College of Osteopathic MedicineClass of 2003
- Duquesne UniversityMS, Biology - Molecular Genetics, 1997 - 1999
Certifications & Licensure
OH State License 2013 - 2025
KY State License 2022 - 2024
PA State License 2003 - 2006- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2023 Jan 26
Roles: Principal Investigator
Publications & Presentations
PubMed
- A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.Meletios A Dimopoulos, Daniel Coriu, Sosana Delimpasi, Ivan Špička, Terry Upchurch
Blood Advances. 2024-10-08 - 9 citationsDaratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke
Leukemia & Lymphoma. 2022-10-01 - 2 citationsProcess, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma.Daanish Hoda, Robert Richards, Edward A Faber, Abhinav Deol, Bradley D Hunter
Future Oncology. 2022-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
